Trial Profile
REAL-WORLD CLINICAL PATTERNS OF CARE AND OUTCOMES AMONG PATIENTS IN AFRICA MIDDLE EAST (AFME) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) RECEIVING SUNITINIB AS FIRST LINE THERAPY (OPTIMISE).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms OPTIMISE
- Sponsors Pfizer
- 23 Dec 2022 Status changed from completed to discontinued.
- 20 Oct 2022 Status changed from recruiting to completed.
- 26 Jul 2021 Planned End Date changed from 1 Jan 2021 to 1 Jan 2023.